Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

Medicine & Life Sciences

• Granulocyte Colony-Stimulating Factor 100%
• Paclitaxel 94%
• Neoplasms 30%
• Myalgia 17%
• Arthralgia 16%
• Cardiac Arrhythmias 13%
• Diphenhydramine 10%
• Factor V 9%
• Ranitidine 9%
• Premedication 9%
• Maximum Tolerated Dose 9%
• Drug and Narcotic Control 8%
• Anaphylaxis 8%
• Peripheral Nervous System Diseases 8%
• Dexamethasone 7%
• Half-Life 6%
• Hypersensitivity 6%
• Area Under Curve 6%
• Outpatients 5%
• Pain 4%
• Incidence 3%
• Therapeutics 1%